Breast Cancer

Steep Decline in Chemotherapy Use for Early-Stage Breast Cancer

The use of chemotherapy to treat women with early-stage breast cancer “declined markedly over time,” according to analysis of data from 2,926 women between the ages of 20 and 79. The trends...

Hematologic Malignancies

Pomalidomide and Low-Dose Dexamethasone in Patients With Multiple Myeloma and Renal Impairment

In a European phase II trial reported in the Journal of Clinical Oncology, Dimopoulos et al found that pomalidomide plus low-dose dexamethasone produced responses in patients with relapsed or...

Issues in Oncology

Up-to-Date Labels for Older Drugs Essential for Appropriate Use

Oncology drug labels, especially those that have been on the market for more than 15 years, may not always be up-to-date. Critical data about safety, efficacy, or prescribing information may...


Advertisement

More Top Stories

Kidney Cancer

Daniel J. George, MD, on RCC: Study Results on Adjuvant Treatment

Hematologic Malignancies

Novel Agent Appears Active in Advanced or Aggressive Systemic Mastocytosis

THE INVESTIGATIONAL agent BLU-285 (avapritinib) has shown significant activity in patients with advanced or aggressive forms of systemic mastocytosis, a rare blood disorder that originates in mast cells, according to the findings of a phase I trial reported at the 2017 American Society of...

Advertisement

FDA Accepts NDA, Grants Priority Review for Ivosidenib in Relapsed or Refractory IDH1-Mutated AML

On February 15, the U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for ivosidenib (AG-120) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation. The NDA was granted Priority Review...

Colorectal Cancer

Thierry André, MD, and Michael J. Overman, MD, on Colorectal Cancer: Results From Two CheckMate-142 Trials

Gastrointestinal Cancer

Ramucirumab/Chemotherapy in Gastric Cancer: ‘Positive’ Trial but Insufficient Benefit

BASED ON EFFICACY seen in the second-line setting for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma, ramucirumab (Cyramza) was evaluated as first-line therapy in the international phase III RAINFALL trial. Although the study met its primary endpoint, with a 25%...

CNS Cancers

Addition of EGFR-Targeting Vaccine to Temozolomide in EGFRvIII-Expressing Glioblastoma

The phase III ACT IV study has shown no survival benefit of adding rindopepimut, a vaccine targeting the epidermal growth factor receptor (EGFR) deletion mutation EGFRvIII, to temozolomide in patients with newly diagnosed EGFRvIII-positive glioblastoma. These findings were reported in The Lancet...

Long-Term Outcomes With PD-L1 Inhibition in Metastatic Urothelial Cancer

As reported by Petrylak et al in JAMA Oncology, long-term follow-up of patients in a phase I study expansion cohort indicated enduring clinical benefit and maintained tolerability of atezolizumab (Tecentriq) in patients with metastatic urothelial carcinoma.  Study Details The study involved...

Prostate Cancer

Nicholas D. James, MBBS, PhD, on Prostate Cancer: Results From the STAMPEDE Trial

Breast Cancer

Updates of Key Studies Differ on Relative Benefit of Nab-Paclitaxel in Breast Cancer

TWO IMPORTANT STUDIES, both updates of earlier findings and presented at the 2017 San Antonio Breast Cancer Symposium, provided different findings as to the relative benefit of nanoparticle albumin-bound (nab)-paclitaxel (Abraxane), vs solvent-based paclitaxel in breast cancer.  “The two studies ...

Advertisement

Chromatin Organization Marker and Cancer-Specific Survival

In a study reported in The Lancet Oncology, Kleppe et al found that a novel marker for chromatin organization in tumor cell nuclei was associated with outcome in a variety of cancer types. Study Details In the study, machine learning algorithms analyzed chromatin organization in 461,000 images of ...